🇺🇸 FDA
Pipeline program

LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

CAAA601A32201

Phase 2 small_molecule active

Quick answer

LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion for somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas is a Phase 2 program (small_molecule) at Advanced Accelerator Applications with 1 ClinicalTrials.gov record(s).

Program details

Company
Advanced Accelerator Applications
Indication
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials